Opdivo PDUFA date for adjuvant melanoma—>10/13/23: https://finance.yahoo.com/news/u-food-drug-administration-accepts-115900042.html The corresponding MAA has been validated by the EMA, starting the review clock. The sBLA and MAA are based on the CHECKMATE-076 study, which showed HR=0.42 for the primary RFS endpoint (#msg-170239823).